Replies to post #352289 on Bioelectronics Corp (BIEL)

[longtrailer]

I just emailed them also:

[e-mail]

Dear Investors Relations Team,

An article from Ad-Hoc News contains the following paragraph:

"Innovation Pipeline and Growth Catalysts
Haleon's developments include Voltaren ActiPatch hybrids integrating gels with wearable tech for chronic pain management, with Swiss pilots eyed for 2027 amid telemedicine growth. Partnerships with sports organizations boost visibility among younger users, driving trial rates. Monetization experiments like pharmacy subscriptions test recurring revenue models."

I am interested in finding out if there is any truth to the statement that "Haleon's developments include Voltaren Actipatch hybrids integrating gels with wearable tech for chronic pain management, with Swiss pilots eyed for 2027 amid telemedicine growth."

I am an investor who finds this idea very intriguing and would appreciate any feedback you can give me. Thank you for your kind consideration. Here is the link to the article: https://www.ad-hoc-news.de/boerse/news/ueberblick/voltaren-gel-haleon-s-powerhouse-in-swiss-pain-relief-market-stability/68683429
Sincerely,
Frederick Collins, Cleveland Heights, Ohio